Recurrent epithelial ovarian cancer: pharmacotherapy and novel therapeutics.

Recurrent epithelial ovarian cancer: pharmacotherapy and novel therapeutics. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Recurrent epithelial ovarian cancer: pharmacotherapy and novel therapeutics. Abstract Text:

Susan C Modesitt,Amir A Jazaeri,Susan C Modesitt,Amir A Jazaeri,

Epithelial ovarian cancer will strike between 1 - 2% of women in developed countries and, unfortunately, it largely remains a lethal disease due to late-stage at diagnosis and the eventual development of chemotherapy resistance. Ovarian cancer is initially treated with surgical resection and chemotherapy (primarily platinum/taxane combinations) and remission can be attained for the majority of patients. Despite this, most women will recur and require multiple further therapies. The purpose of this paper is to review the existing treatment options, including surgery, traditional chemotherapy as well as upcoming novel and targeted therapies that may one day improve outcomes in this disease.

Recurrent epithelial ovarian cancer: pharmacotherapy and novel therapeutics. Publishing Authors By Initials

SC Modesitt,AA Jazaeri,SC Modesitt,AA Jazaeri,

For similar inorganic chemicals: platinum compounds research abstracts see: inorganic chemicals: platinum compounds research

PUBMED ID PMID:

MEDLINE DATE:

Recurrent epithelial ovarian cancer: pharmacotherapy and novel therapeutics. Journal Published:

PUBLICATION TYPE: Review

Journal: Expert opinion on pharmacotherapy

VOLUME: 8

Page Numbers: 2293-305

Journal Abbreviation:

ISSN: 1744-7666

DAY: 29

MONTH: Oct

YEAR: 2007

Recurrent epithelial ovarian cancer: pharmacotherapy and novel therapeutics. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 100897346

Recurrent epithelial ovarian cancer: pharmacotherapy and novel therapeutics. Keywords Mesh Terms:

KEYWORDS: Platinum Compounds

MESH TERMS: therapeutic use

Chemical & Substance for Abstract: Recurrent epithelial ovarian cancer: pharmacotherapy and novel therapeutics. Information

Substance Name: Platinum Compounds

Registry Number: 0

Grant and Affiliation Information for Recurrent epithelial ovarian cancer: pharmacotherapy and novel therapeutics.

AFFILIATION: University of Virginia Health Center, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Box 800712, Charlottesville, VA 22932, USA. scm6h@virginia.edu

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Expert Opin Pharmacother

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Recurrent epithelial ovarian cancer: pharmacotherapy and novel therapeutics Related Publications

• A cost comparison of two strategies for treating stage IB2 cervical cancer.
• A cost-effective analysis of adjuvant therapies for the treatment of stage I endometrial adenocarcinoma.
• Chemoradiation with and without adjuvant extrafascial hysterectomy for IB2 cervical carcinoma.
• Recurrent epithelial ovarian cancer: pharmacotherapy and novel therapeutics.
• Utilization of a uniform grading system for interpreting serous ovarian cancer.